Overview

Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a single dose of pregabalin 300mg in patients receiving medications for sedative-hypnotic withdrawal symptoms will produce meaningful differences in measures of "drug liking" and "drug high" as compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Centre for Addiction and Mental Health
Treatments:
Pregabalin